21:17 , Apr 23, 2019 |  BC Extra  |  Company News

Fulcrum gets rights to GSK's shelved p38 kinase inhibitor

Following the failure of late-stage trials conducted by GSK in acute coronary syndrome and chronic obstructive pulmonary disease, Fulcrum will seek to revive the pharma's losmapimod for a rare genetic disease with an exclusive, worldwide...
16:12 , Apr 5, 2019 |  BC Week In Review  |  Company News

FDA approves Circassia's COPD treatment, AZ gets $20M milestone

Circassia said FDA approved Duaklir Pressair aclidinium bromide/formoterol fumarate to treat chronic obstructive pulmonary disease. The agency also accepted for review an sNDA for Tudorza Pressair aclidinium bromide to include on its label clinical data...
13:06 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
19:12 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

DISEASE CATEGORY: Renal INDICATION: Renal damage Mouse studies suggest inhibiting soluble epoxide hydrolase could help treat renal damage. In a mouse model of diet-induced renal injury, a soluble epoxide hydrolase inhibitor tool compound decreased renal...
20:09 , Mar 1, 2019 |  BC Week In Review  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...
23:11 , Feb 25, 2019 |  BC Extra  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...
22:03 , Feb 15, 2019 |  BC Extra  |  Politics & Policy

NICE provides first scientific advice on patient preference

The National Institute for Health and Care Excellence said on Thursday that it provided its first scientific advice to Novartis AG (NYSE:NVS; SIX:NOVN) on the design of a patient preference study for chronic obstructive pulmonary...
20:04 , Feb 15, 2019 |  BC Week In Review  |  Company News

Mylan launches first U.S. generic of GSK's Advair

Mylan N.V. (NASDAQ:MYL) launched Wixela Inhub salmeterol/fluticasone, the first generic version of Advair Diskus, in the U.S. at a list price 70% less than the branded version. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets Advair Diskus. Both...
01:35 , Feb 15, 2019 |  BC Week In Review  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
21:47 , Feb 14, 2019 |  BC Extra  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...